REGN5458 is a bispecific BCMA/CD3 T cell engaging antibody.

SparkCures ID 351
Developed By Regeneron Pharmaceuticals
Generic Name REGN5458
Treatment Classifications
Treatment Targets

Clinical Trials

Published Results

First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma

December 08, 2019

Results were presented today at the American Society of Hematology (ASH) Annual Meeting from the first two dose groups (3 mg and 6 mg weekly doses).

  • Patients had a median of seven lines of prior systemic therapy, and all had failed CD38 antibody treatment.
  • Responses were observed in 4 of 7 (57%) patients, including 3 of 4 (75%) in the 6 mg dose group.
  • In the 6 mg dose group, 2 patients (50%) were also minimal residual disease (MRD) negative, meaning that no cancer cells were detectable in their bone marrow.